NASDAQ: CLLS - Cellectis S.A.

Lønnsomhet i seks måneder: -25.79%
Utbytte: 0.00%
Sektor: Healthcare

Kampanjeplan Cellectis S.A.

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.

flere detaljer
It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia Therapeutics. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

IPO date 2007-02-07
ISIN US15117K1034
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.cellectis.com
Цена ао 2.57
Prisendring per dag: -6.62% (1.51)
Prisendring per uke: -14.02% (1.64)
Prisendring per måned: -33.8% (2.13)
Prisendring over 3 måneder: -35.44% (2.184)
Prisendring over seks måneder: -25.79% (1.9)
Prisendring per år: -54.22% (3.08)
Prisendring over 3 år: -83.92% (8.77)
Prisendring over 5 år: -89.9% (13.96)
Prisendring over 10 år: 0% (1.41)
Prisendring siden begynnelsen av året: -33.8% (2.13)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 263.54 1
P/BV 2.35 6
P/E 0 0
EV/EBITDA -1.76 0
Total: 3.25

Effektivitet

Navn Betydning Karakter
ROA, % -30.23 0
ROE, % -119.32 0
Total: 0

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0 0
Total: 0

Plikt

Navn Betydning Karakter
Debt/EBITDA -0.4779 10
Total: 10

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % -95.03 0
Lønnsomhet Ebitda, % -25.05 0
Lønnsomhet EPS, % -17.17 0
Total: 0.4
Flere detaljer

Institusjoner Volum Dele, %
Long Focus Capital Management, LLC 4487293 6.25
Capital International Investors 1848804 2.58
Credit Suisse Ag/ 1438255 2
Baillie Gifford and Company 816643 1.14
Principal Financial Group, Inc. 399627 0.56
Macquarie Group Limited 226875 0.32
KBC Group NV 163447 0.23
Oppenheimer & Company Inc. 133143 0.19
Morgan Stanley 76225 0.11
LPL Financial LLC 72187 0.1

ETF Dele, % Lønnsomhet for året, % Utbytte, %
Avantis International Equity ETF 0 6.46 3.80856



Veileder Stillingstittel Betaling Fødselsår
Dr. Andre Choulika Ph.D. Co-Founder, CEO & Director 876.6k 1965 (60 år)
Valerie Cros Principal Financial Officer & Principal Accounting Officer N/A
Mr. Jean Charles Epinat Chief Technological Officer N/A
Dr. Philippe Duchateau Ph.D. Chief Scientific Officer N/A 1963 (62 år)
Mr. Stephan Reynier M.Sc. Chief Regulatory & Pharmaceutical Compliance Officer N/A 1969 (56 år)
Ms. Marie-Bleuenn Terrier General Counsel & Secretary of the Board of Directors N/A 1982 (43 år)
Pascalyne Wilson Director of Communications N/A
Ms. Kyung Nam-Wortman Executive VP & Chief Human Resources Officer N/A 1970 (55 år)
Dr. David j. d. Sourdive Ph.D. Deputy CEO, Executive VP of CMC & Manufacturing and Director 557.84k 1967 (58 år)
Mr. Arthur Stril Interim Chief Financial Officer 1989 (36 år)

Adresse: France, Paris, 8. rue de la Croix Jarry - åpne i Google maps, åpne Yandex-kart
Nettsted: https://www.cellectis.com